Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with adva...
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
About this item
Full title
Author / Creator
Ma, Yuxiang , Xue, Jinhui , Zhao, Yuanyuan , Zhang, Yang , Huang, Yan , Yang, Yunpeng , Fang, Wenfeng , Guo, Ye , Li, Qun , Ge, Xiaoxiao , Sun, Jie , Zhang, Bangyong , Zhang, Yuhan , Xiao, Jinyuan , Zhang, Li and Zhao, Hongyun
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundKN046 is a novel bispecific antibody targeting programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This multicenter phase I trial investigated the safety, tolerability, pharmacokinetics (PK), and efficacy of KN046 in patients with advanced solid tumors.MethodsPatients who failed standard treatment w...
Alternative Titles
Full title
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_95d8c6373ec04b3a82fc11ecb0923947
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_95d8c6373ec04b3a82fc11ecb0923947
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2022-006654
